Rankings
▼
Calendar
AXSM Q4 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AXSM
Axsome Therapeutics, Inc.
$9B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$196M
+65.0% YoY
Gross Profit
$184M
93.7% margin
Operating Income
-$29M
-15.0% margin
Net Income
-$29M
-14.6% margin
EPS (Diluted)
$-0.56
QoQ Revenue Growth
+14.6%
Cash Flow
Operating Cash Flow
-$19M
Free Cash Flow
-$19M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$690M
Total Liabilities
$602M
Stockholders' Equity
$88M
Cash & Equivalents
$323M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$196M
$119M
+65.0%
Gross Profit
$184M
$108M
+69.7%
Operating Income
-$29M
-$73M
+59.5%
Net Income
-$29M
-$75M
+61.9%
Revenue Segments
Product
$195M
100%
Geographic Segments
UNITED STATES
$194M
100%
Non-US
$353,000
0%
← FY 2025
All Quarters